top of page

SCIENTIFIC PROGRAMME

Thursday, April 3, 2025

 

08.30                 Registration Opens

09.30 - 09.40   Welcome Address

Michael von Bergwelt, Munich, Germany

09.40 - 11.10   Plenary Session 1: Tumor Immunology Inside: Novel Players

 

09.40 – 10.10

01.01. Neutrophils in cancer

Mikael Pittet, Geneva, Switzerland

 

10.10 – 10.40             

01.02. Dendritic cells as orchestrators of cancer immunity

Niroshana Anandasabapathy, New York, NY, United States

 

10.40 – 11.10             

01.03. Tregs in the cancer environment

Eliane Piaggio, Paris, France

11.10 - 11.40   Coffee Break

11.40 - 13.10   Plenary Session 2: Expect the Unexpected: Factors Influencing Immune Therapies

11.40 - 12.10   

02.01. The influence of circadian rhythm on IO agent efficacy

Christoph Scheiermann, Geneva, Switzerland

 

12.10 - 12.40   
02.02. Androgen influence on immunotherapy

Megan Ruhland, Portland, OR, United States

 

12.40 - 13.10   
02.03. Local production of glucocorticoids in cancer and its therapeutic relevance

Matthew Taves, Bethesda, MD, United States

13.10 - 13.40   Satellite Symposium - Slot 1

13.40 - 15.00   Lunch & Poster Viewing

15.00 - 17.00   Plenary Session 3: New Targets and New Leads

15.00 - 15.30   
03.01. Proteostatic Stress Response as Novel Opportunity for Cancer Immunotherapy

Zihai Li, Columbus, OH, United States

 

15.30 - 16.00   

03.02. MultiOmics in pushing the frontiers in understanding the tumor microenvironment: Single cell resolution imaging

Matteo Iannacone, Milan, Italy

 

16.00 – 16.15    03.03. Talk from Submitted Abstracts

16.15 – 16.30    03.04. Talk from Submitted Abstracts

16.30 – 16.45    03.05. Talk from Submitted Abstracts

16.45 – 17.00    03.06. Talk from Submitted Abstracts

17.00 - 18.00   Plenary Session 4: Polyspecific Antibody Derivatives

17.00-17.30                

04.01. TCR and TCR mimetics x CD3 bispecific antibodies: Expand the reach of antibodies to intracellular targets

Guillem Argilés, New York, NY, United States

 

17.30-18.00                

04.02. Bispecific gamma-delta T-cell engagers (Gammabodies) against cancer

Hans van der Vliet, Amsterdam, The Netherlands

18.00 - 20.00    Networking Event and Poster Viewing (at the venue)

Friday, April 4, 2025

08.00 – 08.30   Satellite Symposium - Slot 2

08.30 – 09.30   Plenary Session 5: Pro and Con: Local vs Systemic Immunotherapy

08.30 – 09.00             

05.01. Pro-local immunotherapies

Louisa von Baumgarten, Munich, Germany

 

09.00 – 09.30             

05.02. Pro systemic immunotherapy

Mascha Binder, Basel, Switzerland

09.30 – 10.30   Plenary Session 6: Playing with the Devil: Nociception in Cancer Immunotherapy

09.30 – 10.00             

06.01. Triggering alpha2adrenergic receptors for tumor rejection

Jingjing Zhu, Louvain, Belgium

 

10.00 – 10.30             

06.02. Neuro-immune regulation of ILC function in anti-tumor immunity

Camilla Jandus, Geneva, Switzerland

10.30 – 11.00   Coffee Break

11.10 – 12.30    Plenary Session 7: Immune Monitoring – Omics Technology

11.00 – 11.30             

07.01. Using pan-cancer ScRNAseq databases to resolve the tumor microenvironment

tba

 

11.30 – 12.00             

07.02. Resolving the HLA-ligandome in cancer

Juliane Walz, Tübingen, Germany

 

12.00 – 12.30             

07.03. Liquid immunotranscriptomics-derived biomarkers for monitoring response to immunotherapy in metastatic cancer

Pedro Romero, Lausanne, Switzerland

12.30 - 13.00   Satellite Symposium - Slot 3 | Option 1 (30min)

12.30 - 13.30   Satellite Symposium - Slot 3 | Option 2 (60min)

13.00/13.30 – 14.30   Lunch & Poster Viewing

14.30 – 15.15   Plenary Session 8: ITOC 11 Lifetime Achievement Award 

Robert D. Schreiber, St. Louis, MO, United States

15.15 - 16.30   Plenary Session 9: Advancing Cancer Vaccines

15.15 – 15.45             

09.01. Neoantigen selection in tumor and lessons from flu

Paul G. Thomas, Memphis, TN, United States

 

15.45 – 16.15             

09.02. Dysfunctional translation generates aberrant, immunogenic peptides

Wouter Scheper, Amsterdam, The Netherlands

 

16.15 – 16.30    09.03. Talk from Submitted Abstracts

16.30 - 17.00   Coffee Break
 

17.00 - 18.00   Plenary Session 10: Young Researcher Session (from submitted abstracts)

17.00 – 17.15    10.01. Talk from Submitted Abstracts

17.15 – 17.30    10.02. Talk from Submitted Abstracts

17.30 – 17.45    10.03. Talk from Submitted Abstracts

17.45 – 18.00    10.04. Talk from Submitted Abstracts

18.00 - 19.00   Poster Viewing with Presenters

19.15                ITOC 11 Conference Dinner


Saturday, April 5, 2025

08.00 – 09.00    Plenary Session 11: What Cellular Therapies Need to Work

08.00 – 08.30             

11.01. The role of preconditioning in T cell therapy

tba

 

08.30 – 09.00             

11.02. The role of myeloid cells in CAR T cell failure

Camille Bigenwald, Villejuif, France

09.00 – 10.30    Plenary Session 12 Engineering novel Cellular Immunotherapies

09.00 – 09.30             

12.01. Novel targets of TCR therapies

Johanna Olweus, Oslo, Norway

 

09.30 – 10.00             

12.02. Adoptive Cell Therapy, ways to enhance them

Sabine Heitzeneder, Stanford, CA, United States

 

10.00 – 10.30             

12.03. RORing cancer with novel CAR T cells

Michael Hudecek, Würzburg, Germany

10.30 – 11.00    Coffee Break

11.00 – 12.30    Plenary Session 13: Advancing Cellular Therapies with Combinations

11.00 – 11.30             

13.01. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors

Andreas Mackensen, Erlangen, Germany

                    

11.30 – 12.00             

13.02. Targeting TGFbeta-activated kinase-1 activation in microglia to reduce neurotoxicities of CAR T cell therapies

Robert Zeiser, Freiburg, Germany

12.00 – 12.15    13.03. Talk from Submitted Abstracts

12.15 – 12.30    13.04. Talk from Submitted Abstracts

12.30 – 12.45    13.05. Talk from Submitted Abstracts

12.45 – 13.15    Plenary Session 14: Best Poster Awards & Closing Remarks

13.15 – 14.15    Lunch & Farewell

bottom of page